Overview on Medicines Regulation: regulatory cooperation and harmonization in focus
|
|
- Hector Shaw
- 5 years ago
- Views:
Transcription
1 Overview on Medicines Regulation: regulatory cooperation and harmonization in focus Dr Samvel Azatyan Manager, Medicines Regulatory Support Programme Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies World Health Organization 1 Forecasting Global ARV demand and improving access to adult
2 What is medicines regulation? What is special with medicines, compared to other goods / commodities? As a rule, patients are not able to make independent judgement about of the QUALITY, SAFETY and EFFICACY Even doctors and pharmacists have difficulties, unless specially trained.. Medicines regulation is the totality of all measures - legal, administrative and technical - which governments undertake to ensure the safety, efficacy and quality of medicines, as well as the relevance and accuracy of product information. 2 Forecasting Global ARV demand and improving access to adult
3 Why regulating medicines? Consequences of under-regulation (weak regulatory capacity) irrational consumption and prescription; substandard, counterfeit, harmful, useless medicines on the market. Consequences of over- or improper regulation shortage of needed medicines or delayed access; increased costs of medicines due to the cost of regulatory system. 3 Forecasting Global ARV demand and improving access to adult
4 What are the issues? Can all national regulators assess and inspect all the new innovative products that come to their markets? Can and should all the regulators assess and inspect all the generic medicines? Does repetitive assessment and inspections give added value? How to build confidence in scientific assessments/ inspections carried out by other parties? How regulators can best contribute to the public health with the (limited) resources they have? 4 Forecasting Global ARV demand and improving access to adult
5 Can all national regulators assess and inspect all products that come to their markets? In theory, and only in theory, YES But who can pay the bill? Thus, in practice, NO 5 Forecasting Global ARV demand and improving access to adult
6 Differences in regulatory capacity Due to chronic shortages of human and technical resources, many regulatory authorities do not have the full capacity to perform all regulatory functions; Weak regulatory frameworks and lack of enforcement lead to various bottlenecks, limiting access to essential medicines. 193 WHO Member States: 20% 50% 30% Developed Varying Limited 6 Forecasting Global ARV demand and improving access to adult
7 Does repetitive assessment and inspections give added value? YES, provided the previous assessment has been based on different (lower) set of standards, or missed important issues (due to different qualifications, views); Usually NO, if the same standards are used; Usually NO, if the capacity for assessment is not present, or does not equal to the one of the first assessment; Duplicate efforts, or trust colleagues? That is the question! 7 Forecasting Global ARV demand and improving access to adult
8 How regulators can best contribute to the public health with the resources they have? Avoid doing things that do not give added value, concentrate on things that do give added value; Concentrate on high risk areas/products; Be pragmatic: Nice to know forget it, need to know get it! And learn making difference between the two; Cooperate with partners in order to increase regulatory capacity by elimination of duplicated activities Facilitated by comparable standards and administrative requirements. 8 Forecasting Global ARV demand and improving access to adult
9 Sharing of expertise vs. recognition of decision Acceptance of expertise is not equal to acceptance of decision Acceptance of expertise is sovereign and complex regulatory decision of NRA based on scientific arguments and confidence; may be applied case to case; is followed by formal independent decision according to national legislation and mandate of national MRA; Acceptance of decision is a formal legal act, frequently requiring international treaties; may modify liabilities of involved parties and requires legal specification of acceptance and non-acceptance. 9 Forecasting Global ARV demand and improving access to adult
10 New regulatory pathways Smaller or less resourced regulatory authorities often rely on the approvals or opinions issued by the well-resourced regulatory authorities Examples of this type of initiatives include, but are not limited to: WHO PQP - HIV/AIDS, TB, malaria, RH, paediatric therapy; US PEPFAR - HIV/AIDS; EU Article 58 assessment of products for use outside the European Union; Canada's Access to Medicines Regime assessment of products according to WHO Model List of Essential Medicines; Other orphan medicines, paediatric medicines. 10 Forecasting Global ARV demand and improving access to adult
11 WHO approaches for regulatory support Developing evidence - assessments of regulatory systems worldwide (around 50 NMRAs assessed in all 6 regions); Providing direct technical support (capacity building, tools and guidance) to regions and countries (with PQ and IVB); Stimulating / initiating collaboration between regulators from various countries on various regulatory activities (from "North South" to "South South"); Facilitating the establishment of "Centres of excellence" for regulatory affairs; Promoting harmonization. 11 Forecasting Global ARV demand and improving access to adult
12 Regulatory harmonization In a broad sense harmonization means harmonization of technical requirements for medicines regulation, i.e., legislations, guidelines, procedures, etc. These requirements relate to the quality, safety and efficacy of the medicinal products; These requirements differ in complexity, from one type of marketing authorization application to another; To start with innovators or with generics? Or both? 12 Forecasting Global ARV demand and improving access to adult
13 What we do mean under Harmonization? True harmonization goes further than just common documentation; It requires effective communication and collaboration aimed at building capacity and trust (e.g., information sharing, recognition and joint working); In combination, these activities can lead to similar or collaborative approaches to drug registration; Paving the way for mutual recognition and/or centralized registration (if desired) in the longer-term future. 13 Forecasting Global ARV demand and improving access to adult
14 What we do not mean under Harmonization? Harmonization does not mean a loss of national sovereignty / autonomy (and certainly not in the early stages) Common documentation stipulates the requirements for registration; Better communication enables countries to chose which information they will use; Collaborative mechanisms, such as joint assessments or inspections, does not imply collaborative decision-making! In all cases the registration decision itself stays firmly in the hands of sovereign nations 14 Forecasting Global ARV demand and improving access to adult
15 Scope and objectives for harmonization Objective of drug regulation: TO IMPROVE AND PROMOTE PUBLIC HEALTH In case harmonization is supported by International Community main objective should be: MEASURABLE PUBLIC HEALTH GAINS There may be other gains, but these should be in the centre. 15 Forecasting Global ARV demand and improving access to adult
16 Potential public health gains from harmonization Less risk of being harmed by medicines (safety risks combined with no treatment effect risks) as gradual improvement of quality, safety and efficacy of products on the markets is expected; More rapid access to needed medicines (high priority essential medicines, new medicines ); Better value for money (both for out of pocket and public funds) as no waste on substandard and of dubious safety and efficacy medicines; Increasing trust in generic medicines (also better value for money). 16 Forecasting Global ARV demand and improving access to adult
17 Potential gains have to be balanced with potential losses Increased price level of medicines (quality has its price); Reduced access not all medicines on the market may meet new harmonized standards; Increasing price for medicines regulation (harmonization has also its price); Domestic manufacture may not always win; Wholesale and retail businesses may loose many of the products that were bestsellers for them. 17 Forecasting Global ARV demand and improving access to adult
18 Potential scope for harmonization in Africa Harmonization of technical requirements Generic drugs vs NCEs move from generics to NCEs Priorities (CTD, modules for generics, GMP), timeframes and working methods for creation of guidelines to be determined; Implementation of harmonized technical requirements; Establishing for priority products a special pathway one set of assessments/inspections access to all markets Either via "centralized procedure" (one application, one process and one result for all) or "mutual recognition" (same application for all or some, one MRA does the job and others recognize without duplication). 18 Forecasting Global ARV demand and improving access to adult
19 Regulatory harmonization in Africa Africa a continent of huge diversity and complex unity, with numerous Regional Economic Communities (REC); overlaps and politically complicated environment. 19 Forecasting Global ARV demand and improving access to adult
20 African Medicines Registration Harmonization Initiative (AMRHI) Process started with the informal consultations in ICDRA Meeting, September 2008, Bern, Switzerland; In response to the growing recognition of the potential benefits of harmonizing medicines registration in Africa, a WHO concept paper was developed to describe a proposed approach to supporting drug registration harmonization within and across African regional groupings. WHO Drug Information, Volume 22, Number 3, Forecasting Global ARV demand and improving access to adult
21 African Medicines Registration Harmonization Initiative (AMRHI) Further discussions and orientation in the meeting in Johannesburg, South Africa, February 2009, organized jointly by BMGF, NEPAD, William J. Clinton Foundation and the WHO. The purpose of the meeting was: to explore the possibilities of supporting medicine registration harmonization, as an initial first step to broader regulatory harmonization within African Regional Economic Communities (RECs) and organizations, and to initiate a strategic approach to develop project proposals for mobilizing the necessary financial and technical resources to support RECs undertaking medicine registration harmonization. 21 Forecasting Global ARV demand and improving access to adult
22 African Medicines Registration Harmonization Initiative (AMRHI) Donor partners, NEPAD and WHO confirmed their interest in supporting the RECs, including necessary actions to support national implementation, strengthen national regulatory agencies and promote inter-rec and continental exchange of information, coordination and technical consistency. Their strategic approach was to invite summary project proposals from committed RECs and seek financial and technical support for the most sound and promising proposals among them. 22 Forecasting Global ARV demand and improving access to adult
23 African Medicines Registration Harmonization Initiative (AMRHI) next steps for further implementation of the project: By 31st May 2009 RECs are invited to submit to WHO and NEPAD a summary project proposal in support of regional medicine registration harmonization. A draft format and a suggested scope and outline are available. NEPAD and WHO are willing to give limited technical support to the development of such regional proposals. April-May 2009: Submission of summary project proposals; June 2009: Review of proposals and feedback to RECs; July-October 2009: Selected RECs to submit their full project proposals to NEPAD & WHO; November-December 2009: Review of full project proposals by Project consortium and submission to interested Donors; January-June 2010: Implementation of first approved projects. 23 Forecasting Global ARV demand and improving access to adult
24 Conclusions Sharing of information, collaboration and harmonization can help reduce workload and improve overall regulatory performance. It can help to direct the expert knowledge and resources to performance of the functions that can improve public health and facilitate access to essential medicines; Formation of effective networks between regulatory authorities nationally and internationally may facilitate sharing of scarce resources and eliminate duplicating of activities; Harmonization could contribute in building regulatory capacity and trust, which is an important achievement in its own right. 24 Forecasting Global ARV demand and improving access to adult
25 Thank you! Photo by: 25 Forecasting Global ARV demand and improving access to adult
Quality assurance in the supply chain for pharmaceuticals from the WHO perspective
1 Quality assurance in the supply chain for pharmaceuticals from the WHO perspective Dr Sabine Kopp Quality Assurance and Safety: Medicines Medicines Policy and Standards World Health Organization Presentation
More informationWHO Regulatory Systems Strengthening Program
WHO Regulatory Systems Strengthening Program MVP RHT RSS CRS www.who.int Minimal capacity met Eligibility for vaccine PQ WHO listed NRAs WHO NRA 5 step capacity building Development of NRA benchmarking
More informationASEAN Regulatory Harmonisation and Approval Process
ASEAN Regulatory Harmonisation and Approval Process Selvaraja Seerangam National Pharmaceutical Control Bureau Ministry of Health Malaysia Open Forum on Key Issues on TB Drug Development- 18-19 August
More informationConvergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA
EUnetHTA European network for Health Technology Assessment Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA University of Tokyo, October 24,
More informationARTEMISININ RESISTANCE IN THE GREATER MEKONG SUBREGION
1 ARTEMISININ RESISTANCE IN THE GREATER MEKONG SUBREGION Key messages The situation in the Greater Mekong Subregion is critical. We are at a tipping point. If resistance to artemisinin emerges elsewhere,
More informationNZFSA Policy on Food Safety Equivalence:
NZFSA Policy on Food Safety Equivalence: A Background Paper June 2010 ISBN 978-0-478-33725-9 (Online) IMPORTANT DISCLAIMER Every effort has been made to ensure the information in this report is accurate.
More informationDraft Plan of Action Chair's Text Status 3 May 2008
Draft Plan of Action Chair's Text Status 3 May 2008 Explanation by the Chair of the Drafting Group on the Plan of Action of the 'Stakeholder' Column in the attached table Discussed Text - White background
More informationIP KEY SOUTH EAST ASIA ANNUAL WORK PLAN FOR 2018
ANNUAL WORK PLAN FOR 2018 IP KEY SOUTH EAST ASIA ANNUAL WORK PLAN FOR 2018 IP Key South East Asia is an EU Project designed to support the Free Trade Agreement (FTA) talks and Intellectual Property Dialogues
More informationInterim Report on the Heiligendamm Process at the G8 Summit in Hokkaido Toyako 7 to 9 July 2008
Interim Report on the Heiligendamm Process at the G8 Summit in Hokkaido Toyako 7 to 9 July 2008 Prepared by the Steering Committee of the Heiligendamm Process consisting of the personal representatives
More informationIGDRP Mission, Scope, How it works
IGDRP Mission, Scope, How it works IGDRP-EDQM Workshop Strasbourg, France 13 May 2016 Dr. Craig Simon Associate Director, Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada
More informationHealth Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities
Health Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities Aleksandra Torbica, Carlo Federici, Rosanna Tarricone Centre for Research on Health and
More informationSwissmedic, Swiss Agency for Therapeutic Products
PMDA International Forum, 8 February 2014 Swissmedic, Swiss Agency for Therapeutic Products Jürg H. Schnetzer, Executive Director Grüezi. Bonjour. Buongiorno. Allegra. 2 Overview Swissmedic Introduction
More informationA stronger system to protect the health and safety of Canadians. Exploring the Future of the Food Regulatory Framework Under the Food and Drugs Act
A stronger system to protect the health and safety of Canadians Exploring the Future of the Food Regulatory Framework Under the Food and Drugs Act Purpose and Scope To stimulate a discussion about how
More informationNCRIS Capability 5.7: Population Health and Clinical Data Linkage
NCRIS Capability 5.7: Population Health and Clinical Data Linkage National Collaborative Research Infrastructure Strategy Issues Paper July 2007 Issues Paper Version 1: Population Health and Clinical Data
More informationInternational Conference on Research Infrastructures 2014
EUROPEAN COMMISSION [CHECK AGAINST DELIVERY] Máire GEOGHEGAN-QUINN European Commissioner responsible for Research, Innovation and Science International Conference on Research Infrastructures 2014 Conference
More informationEnforcement of Intellectual Property Rights Frequently Asked Questions
EUROPEAN COMMISSION MEMO Brussels/Strasbourg, 1 July 2014 Enforcement of Intellectual Property Rights Frequently Asked Questions See also IP/14/760 I. EU Action Plan on enforcement of Intellectual Property
More informationTowards malaria elimination: ADB-supported work at Myanmar FDA
Towards malaria elimination: ADB-supported work at Myanmar FDA Valerio Reggi 25 January 2018 Disclaimer: The views expressed in this paper/presentation are the views of the author and do not necessarily
More informationGlobal Harmonization Task Force
Global Harmonization Task Force How to minimize risks without constraining innovation and harming free trade The role of international standards And their application at regional and national levels Cornelis
More informationA Brief Introduction to the Regulatory Environment of Medical Device Supervision. CFDA Department of Legal Affairs Liu Pei
A Brief Introduction to the Regulatory Environment of Medical Device Supervision CFDA Department of Legal Affairs Liu Pei Development Trend of Medical Device Industry Development Opportunities of Medical
More informationExtract of Advance copy of the Report of the International Conference on Chemicals Management on the work of its second session
Extract of Advance copy of the Report of the International Conference on Chemicals Management on the work of its second session Resolution II/4 on Emerging policy issues A Introduction Recognizing the
More informationCurrent Status and Challenges of Bilateral/Multilateral Meetings
Current Status and Challenges of Bilateral/Multilateral Meetings Junko Sato, PhD International Liaison Officer PMDA 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views and
More informationSBI/SBSTA: Parties move forward on economic diversification and just transition work
122 SBI/SBSTA: Parties move forward on economic diversification and just transition work Kuala Lumpur, 6 June (Hilary Chiew) Parties to the UNFCCC at the recently concluded climate talks in Bonn agreed
More informationthe Companies and Intellectual Property Commission of South Africa (CIPC)
organized by the Companies and Intellectual Property Commission of South Africa (CIPC) the World Intellectual Property Organization (WIPO) the International Criminal Police Organization (INTERPOL) the
More informationGlobal strategy and plan of action on public health, innovation and intellectual property
SIXTY-FIRST WORLD HEALTH ASSEMBLY WHA61.21 Agenda item 11.6 24 May 2008 Global strategy and plan of action on public health, innovation and intellectual property The Sixty-first World Health Assembly,
More informationIV/10. Measures for implementing the Convention on Biological Diversity
IV/10. Measures for implementing the Convention on Biological Diversity A. Incentive measures: consideration of measures for the implementation of Article 11 Reaffirming the importance for the implementation
More informationPROMOTING QUALITY AND STANDARDS
PROMOTING QUALITY AND STANDARDS 1 PROMOTING QUALITY AND STANDARDS Strengthen capacities of national and regional quality systems (i.e. metrology, standardization and accreditation) Build conformity assessment
More informationThe 45 Adopted Recommendations under the WIPO Development Agenda
The 45 Adopted Recommendations under the WIPO Development Agenda * Recommendations with an asterisk were identified by the 2007 General Assembly for immediate implementation Cluster A: Technical Assistance
More informationProgress in FDA s Drug Product Quality Initiative. Janet Woodcock, M.D. November 13, 2003
Progress in FDA s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003 Impetus for Initiative: Modernization and continuous improvement in pharmaceutical manufacturing sector slow compared
More informationMedical Technology Association of NZ. Proposed European Union/New Zealand Free Trade Agreement. Submission to Ministry of Foreign Affairs & Trade
Medical Technology Association of NZ Proposed European Union/New Zealand Free Trade Agreement Submission to Ministry of Foreign Affairs & Trade February 2016 1 Introduction The Medical Technology Association
More information28 March Report of the Working Group on Pharmaceuticals and Public Health of the High Level Committee on Health.
PHARMACEUTICALS AND PUBLIC HEALTH IN THE EU: PROPOSALS TO THE HIGH LEVEL COMMITTEE ON HEALTH FOR POLICIES AND ACTIONS IN THE FRAMEWORK OF THE TREATY OF AMSTERDAM a) 28 March 2000 a) Report of the Working
More informationWIPO Development Agenda
WIPO Development Agenda 2 The WIPO Development Agenda aims to ensure that development considerations form an integral part of WIPO s work. As such, it is a cross-cutting issue which touches upon all sectors
More informationEDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE : 20 YEARS OF EXPERIENCE March EDQM, Strasbourg, France ABSTRACTS
EDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE 1992-2012: 20 YEARS OF EXPERIENCE 22-23 March 2012 EDQM, Strasbourg, France ABSTRACTS PLENARY SESSION, 22 March 2012 ABSTRACT 1.3 The Evolution
More information13-17 OCTOBER 2008 AU/MIN/ CAMRMRD /4(I) ADDIS ABABA DECLARATION ON DEVELOPMENT AND MANAGEMENT OF AFRICA S MINERAL RESOURCES.
AFRICAN UNION UNION AFRICAINE UNIÃO AFRICANA Addis Ababa, ETHIOPIA P. O. Box 3243 Telephone 517 700 Fax: +251-1-517844 AU CONFERENCE OF MINISTERS RESPONSIBLE 1 ST ORDINARY SESSION 13-17 OCTOBER 2008 AU/MIN/
More informationEXPLORATION DEVELOPMENT OPERATION CLOSURE
i ABOUT THE INFOGRAPHIC THE MINERAL DEVELOPMENT CYCLE This is an interactive infographic that highlights key findings regarding risks and opportunities for building public confidence through the mineral
More informationSupporting Innovation through Regulation and Science
Supporting Innovation through Regulation and Science Larry O Dwyer, Scientific Affairs Manager PEARRL Regulatory Science Symposium 21 st June 2017, School of Pharmacy, UCC Overview of Presentation Drivers
More informationExpert Group Meeting on
Aide memoire Expert Group Meeting on Governing science, technology and innovation to achieve the targets of the Sustainable Development Goals and the aspirations of the African Union s Agenda 2063 2 and
More informationParenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy)
Parenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy) BACKGROUND (Reason or Purpose) The purpose of this Policy is to provide clear principles and guidance about
More informationOMCL Network of the Council of Europe GENERAL DOCUMENT
OMCL Network of the Council of Europe GENERAL DOCUMENT PA/PH/OMCL (09) 87 4R OMCL Network support for the implementation of the CoE MEDICRIME Convention Full document title and reference How the OMCL Network
More informationInitial draft of the technology framework. Contents. Informal document by the Chair
Subsidiary Body for Scientific and Technological Advice Forty-eighth session Bonn, 30 April to 10 May 2018 15 March 2018 Initial draft of the technology framework Informal document by the Chair Contents
More informationReflection Paper on synergies between regulatory and HTA issues. DG SANTE Unit B4 Medical products: safety, quality, innovation
Reflection Paper on synergies between regulatory and HTA issues DG SANTE Unit B4 Medical products: safety, quality, innovation STAMP meeting, 28 June 2016 Outline Aim of the Reflection Paper Drafting process
More informationCOUNCIL OF THE EUROPEAN UNION. Brussels, 9 December 2008 (16.12) (OR. fr) 16767/08 RECH 410 COMPET 550
COUNCIL OF THE EUROPEAN UNION Brussels, 9 December 2008 (16.12) (OR. fr) 16767/08 RECH 410 COMPET 550 OUTCOME OF PROCEEDINGS of: Competitiveness Council on 1 and 2 December 2008 No. prev. doc. 16012/08
More informationITAC RESPONSE: Modernizing Consent and Privacy in PIPEDA
August 5, 2016 ITAC RESPONSE: Modernizing Consent and Privacy in PIPEDA The Information Technology Association of Canada (ITAC) appreciates the opportunity to participate in the Office of the Privacy Commissioner
More informationTechnical Assistance. Programme of Activities
Technical Assistance Programme of Activities 2011-2012 July 2011 The present programme of technical assistance activities reflects the decisions taken at the fifth meeting of the Conference of the Parties
More informationAn Essential Health and Biomedical R&D Treaty
An Essential Health and Biomedical R&D Treaty Submission by Health Action International Global, Initiative for Health & Equity in Society, Knowledge Ecology International, Médecins Sans Frontières, Third
More informationOverview of Intellectual Property Policy and Law of China in 2017
CPI s Asia Column Presents: Overview of Intellectual Property Policy and Law of China in 2017 By LIU Chuntian 1 & WANG Jiajia 2 (Renmin University of China) October 2018 As China s economic development
More informationBuenos Aires Action Plan
STUDY GROUP 2 QUESTION 4/2 Assistance to developing countries 1 for implementing conformance and interoperability programmes and combating counterfeit information and communication technology equipment
More informationPatented Medicine Prices Review Board P M P R B GUIDELINES REFORM. 15 th Annual Market Access Summit. Douglas Clark Executive Director PMPRB
Patented Medicine Prices Review Board P M P R B GUIDELINES REFORM Douglas Clark Executive Director PMPRB 15 th Annual Market Access Summit Background Canada enacted a two-fold reform of its drug patent
More informationPan-Canadian Trust Framework Overview
Pan-Canadian Trust Framework Overview A collaborative approach to developing a Pan- Canadian Trust Framework Authors: DIACC Trust Framework Expert Committee August 2016 Abstract: The purpose of this document
More informationUNITAID s approach to funding innovations in TB diagnosis and treatment Robert Matiru & Janet Ginnard, UNITAID Geneva, 29 April 2015
UNITAID UNITAID s approach to funding innovations in TB diagnosis and treatment Robert Matiru & Janet Ginnard, UNITAID Geneva, 29 April 2015 Page 2 UNITAID's role in the global response By connecting the
More informationMedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017)
MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017) Table of Contents Executive Summary...3 The need for healthcare reform...4 The medical technology industry
More informationEUREKA in the ERA INTRODUCTION
A strategy towards becoming a leading ERA innovation stakeholder to contribute to growth and job creation for the benefit of European industry Final version 27 April 2015 INTRODUCTION The objective of
More information8 th Annual Meeting of OECD-CESEE Senior Budget Officials
8 th Annual Meeting of OECD-CESEE Senior Budget Officials Brian Olden Tallinn, Estonia 28-29 June 2012 IMF s new vision for capacity building Economic difficulties experienced in many parts of the world
More informationReport OIE Animal Welfare Global Forum Supporting implementation of OIE Standards Paris, France, March 2018
Report OIE Animal Welfare Global Forum Supporting implementation of OIE Standards Paris, France, 28-29 March 2018 1. Background: In fulfilling its mandate to protect animal health and welfare, the OIE
More informationDOWNLOAD PDF OCEANS GOVERNANCE AND MARITIME STRATEGY
Chapter 1 : David Wilson, Dick Sherwood's Oceans Governance and Maritime Strategy PDF - AAPC E-boo International ocean governance is about managing and using the world's oceans and their resources in ways
More informationGetting the evidence: Using research in policy making
Getting the evidence: Using research in policy making REPORT BY THE COMPTROLLER AND AUDITOR GENERAL HC 586-I Session 2002-2003: 16 April 2003 LONDON: The Stationery Office 14.00 Two volumes not to be sold
More informationA/AC.105/C.1/2014/CRP.13
3 February 2014 English only Committee on the Peaceful Uses of Outer Space Scientific and Technical Subcommittee Fifty-first session Vienna, 10-21 February 2014 Long-term sustainability of outer space
More informationThe International Pharmacopoeia Overview
The International Pharmacopoeia Overview Prepared by Caroline Mendy Technical Officer - Quality Assurance and Safety: Medicines The International Pharmacopoeia P Content & Scope WHO Expert Committee on
More informationCOLLABORATION PROTOCOL BY AND BETWEEN THE CITY OF CAPE TOWN AND THE CAPE HIGHER EDUCATION CONSORTIUM
COLLABORATION PROTOCOL BY AND BETWEEN THE CITY OF CAPE TOWN AND THE CAPE HIGHER EDUCATION CONSORTIUM COLLABORATION PROTOCOL by and between the CITY OF CAPE TOWN (Hereinafter referred to as the CITY ) Duly
More informationA Focus on Health Data Infrastructure, Capacity and Application of Outcomes Data
External Review of Pan-Canadian Health Organizations Thank you for the opportunity to provide input for your ongoing review of the Pan- Canadian Health Organizations (PCHOs). This submission is made on
More informationFood Product Standards to Support Exports
Food Product Standards to Support Exports March 14, 2018 Lusaka, Zambia Presentation Overview GMA Background Core Regulatory Principles to Support Food/Ag Exports Science-Based Standards Regulatory Coherence
More informationGUIDELINES SOCIAL SCIENCES AND HUMANITIES RESEARCH MATTERS. ON HOW TO SUCCESSFULLY DESIGN, AND IMPLEMENT, MISSION-ORIENTED RESEARCH PROGRAMMES
SOCIAL SCIENCES AND HUMANITIES RESEARCH MATTERS. GUIDELINES ON HOW TO SUCCESSFULLY DESIGN, AND IMPLEMENT, MISSION-ORIENTED RESEARCH PROGRAMMES to impact from SSH research 2 INSOCIAL SCIENCES AND HUMANITIES
More informationEstablishing a Development Agenda for the World Intellectual Property Organization
1 Establishing a Development Agenda for the World Intellectual Property Organization to be submitted by Brazil and Argentina to the 40 th Series of Meetings of the Assemblies of the Member States of WIPO
More informationEUROPEAN COMMISSION Directorate-General for Communications Networks, Content and Technology CONCEPT NOTE
EUROPEAN COMMISSION Directorate-General for Communications Networks, Content and Technology 1. INTRODUCTION CONCEPT NOTE The High-Level Expert Group on Artificial Intelligence On 25 April 2018, the Commission
More informationDecember Eucomed HTA Position Paper UK support from ABHI
December 2008 Eucomed HTA Position Paper UK support from ABHI The Eucomed position paper on Health Technology Assessment presents the views of the Medical Devices Industry of the challenges of performing
More informationDRAFT. "The potential opportunities and challenges for SMEs in the context of the European Trade Policy:
DRAFT "The potential opportunities and challenges for SMEs in the context of the European Trade Policy: Brussels - June 24th, 2014 European Economic and Social Committee V. President Giuseppe Oliviero
More informationEU Cooperation on Health Technology Assessment
Strategy for EU Cooperation on Health Technology Assessment Strategy for EU cooperation on Health Technology Assessment (HTA) The HTA Network is a voluntary network, set up by Directive2011/24 (article
More informationPART III: CROSS-CUTTING ISSUES
PART III: CROSS-CUTTING ISSUES Partnerships for transformative Blue Economy actions Situation statement In a globalized world, nations and groups cannot effectively thrive in isolation. This is particularly
More informationSME support under Horizon 2020 Diana GROZAV Horizon 2020 SME NCP Center of International Projects
Horizon 2020 Information Day 11 November 2015 SME support under Horizon 2020 Diana GROZAV Horizon 2020 SME NCP Center of International Projects SME: Key Statistics 20.35 Million SMEs 85 % of new jobs 58%
More informationWIPO Intergovernmental Committee on Intellectual Property, Genetic Resources, Traditional Knowledge and Folklore, Sixth Session, March 2004
WIPO Intergovernmental Committee on Intellectual Property, Genetic Resources, Traditional Knowledge and Folklore, Sixth Session, 15-19 March 2004 Statement by the Secretariat of the Convention on Biological
More informationDRAFT TEXT on. Version 2 of 9 September 13:00 hrs
DRAFT TEXT on SBSTA 48.2 agenda item 5 Development and transfer of technologies: Technology framework under Article 10, paragraph 4, of the Paris Agreement Version 2 of 9 September 13:00 hrs Elements of
More informationEnhancing SMEs Participation in Global Production Chains by Creation of Common Database
2012/SMEWG34/023 Agenda Item: 14.1.1 Enhancing SMEs Participation in Global Production Chains by Creation of Common Database Purpose: Information Submitted by: Russia 34 th Small and Medium Enterprises
More informationGary Condran Associate Director Bureau of Pharmaceutical Sciences, Therapeutic Product Directorate, HPFB, Health Canada
Gary Condran Associate Director Bureau of Pharmaceutical Sciences, Therapeutic Product Directorate, HPFB, Health Canada EDQM International Conference 19-20 September 2017 1 Concept History Mission Objectives
More informationPresidential CEO Investment Summit and Awards 2016
Presidential CEO Investment Summit and Awards 2016 28-29 January 2016, Addis Ababa, Ethiopia Uniting African Nations for Investment Co-Hosts: Official Summit Carrier: Programme The Ai Presidential CEO
More informationEU, USA and Japan (II) Reports from Regulators on Exchange Assignments
EU, USA and Japan (II) Reports from Regulators on Exchange Assignments Yoshikazu Hayashi MHLW/PMDA Liaison at EMA PMDA 24th Annual EuroMeeting 26-28 March 2012 Copenhagen, Denmark Disclaimer The views
More informationInternational initiatives in data sharing: OECD, CODATA and GICSI. Yukiko Fukasaku Innovmond Padova 21 September 2007
International initiatives in data sharing: OECD, CODATA and GICSI Yukiko Fukasaku Innovmond Padova 21 September 2007 OECD Recommendation with Principles and Guidelines on Access to Research Data from Public
More informationJoint ILAC CIPM Communication regarding the. Accreditation of Calibration and Measurement Services. of National Metrology Institutes.
Joint ILAC CIPM Communication regarding the Accreditation of Calibration and Measurement Services of National Metrology Institutes 7 March 2012 Authorship This document was prepared by the International
More informationAPEC Internet and Digital Economy Roadmap
2017/CSOM/006 Agenda Item: 3 APEC Internet and Digital Economy Roadmap Purpose: Consideration Submitted by: AHSGIE Concluding Senior Officials Meeting Da Nang, Viet Nam 6-7 November 2017 INTRODUCTION APEC
More informationGenetic Resources and Intellectual Property: Recent developments under the Convention on Biological Diversity
Genetic Resources and Intellectual Property: Recent developments under the Convention on Biological Diversity 15 September, 2004 Secretariat of the Convention on Biological Diversity Dan B. Ogolla OUTLINE
More informationCanadian Health Food Association. Pre-budget consultations in advance of the 2018 budget
Canadian Health Food Association Submission to the House of Commons Standing Committee on Finance Pre-budget consultations in advance of the 2018 budget Executive Summary Every year, $7 billion is contributed
More informationEXECUTIVE BOARD MEETING METHODOLOGY FOR DEVELOPING STRATEGIC NARRATIVES
EXECUTIVE BOARD MEETING METHODOLOGY FOR DEVELOPING STRATEGIC NARRATIVES EXECUTIVE BOARD MEETING METHODOLOGY FOR DEVELOPING STRATEGIC NARRATIVES 1.Context and introduction 1.1. Context Unitaid has adopted
More informationE5 Implementation Working Group Questions & Answers (R1) Current version dated June 2, 2006
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E5 Implementation Working Group & (R1) Current version dated June 2, 2006 ICH Secretariat,
More informationII. The mandates, activities and outputs of the Technology Executive Committee
TEC/2018/16/13 Technology Executive Committee 27 February 2018 Sixteenth meeting Bonn, Germany, 13 16 March 2018 Monitoring and evaluation of the impacts of the implementation of the mandates of the Technology
More information(EC) ), 11(8) 347/ /2009, (EC)
ENTSOs consistent and interlinked electricity and gas model in accordance with Article 11(8) of Regulation (EU) No 347/2013 of the European Parliament and of the Council of 17 April 2013 21 December 2016
More informationCounterfeit Medicines Toolkit 4. Information about the International Medical Products Anti-Counterfeiting Taskforce (IMPACT)
Counterfeit Medicines Toolkit 4. Information about the International Medical Products Anti-Counterfeiting Taskforce (IMPACT) 1 International Collaboration: A Request of Medicine Regulatory Authorities
More informationAfrican Civil Society Meeting
African Civil Society Meeting Intergovernmental Working Group on Intellectual Property, Innovation and Health Topic: Considering Domestic Manufacturing Issues Nairobi Kenya 28-29 August 2007 DR W.O. WANYANGA
More informationReport on the linkage modalities and the rolling workplan of the Technology Executive Committee for
United Nations Distr.: General 12 March 2012 Original: English Subsidiary Body for Scientific and Technological Advice Thirty-sixth session Bonn, 14 25 May 2012 Item X of the provisional agenda Subsidiary
More informationNanomaterials: Applications, Implications and Safety Management in the SAICM Context Rob Visser
Nanomaterials: Applications, Implications and Safety Management in the SAICM Context Rob Visser The Regulatory Challenge of Nanotechnology 20 January 2012 Bern, Switzerland 1 SAICM context: ICCM 2 considered
More informationPresentation of the results. Niels Gøtke, Chair of the expert group and Effie Amanatidou, Rapporteur
Presentation of the results Niels Gøtke, Chair of the expert group and Effie Amanatidou, Rapporteur Purpose and scope of the evaluation Methodology and basic figures for ERA-NET Cofund Efficiency of ERA-NET
More informationTERMS OF REFERENCE Development of South -Western Indian Ocean (SWIO) Fisheries Accord for Shared Fish Stocks
28 th May 2013 TERMS OF REFERENCE Development of South -Western Indian Ocean (SWIO) Fisheries Accord for Shared Fish Stocks 1. Overview The African Union- InterAfrican Bureau for Animal Resources (AU-IBAR)
More informationHealth Technology Assessment and the European Network for HTA
Health Technology Assessment and the European Network for HTA www.eunethta.eu Marcial Velasco Garrido, Technische Universität Berlin for the European Network for HTA, EUnetHTA Outline What is Health Technology
More informationIntergovernmental Authority on Development (IGAD)
The African Regional Economic Communities and Africa-EU STI co-operation Workshop with the African Regional Economic Communities (RECs), 4 th + 5 th February 2015, Pretoria, South Africa 1 IGAD OVERVIEW
More informationTRIPS and Access to Medicines. WR Briefing
TRIPS and Access to Medicines WR Briefing Outline What is TRIPS How does it affect access to medicines What are the TRIPS flexibilities? What are extra-trips provisions? How do the extra-trips provisions
More informationBC RC SC UNITED NATIONS. on Persistent. English only. Organic Pollutants. Certain. Eighth meeting. Their Disposal. Item. Geneva, 24 April 5 May 2017
UNITED NATIONS Basel Convention on the Control of Transboundary Movements of Hazardous Wastes and Their Disposal Rotterdam Conventionn on the Prior Informed Consent Procedure for Certain Hazardous Chemicals
More informationGuidance on the anonymisation of clinical reports for the purpose of publication
Guidance on the anonymisation of clinical reports for the purpose of publication Stakeholder meeting 6 July 2015, London Presented by Monica Dias Policy Officer An agency of the European Union Scope and
More informationStrategic Plan for CREE Oslo Centre for Research on Environmentally friendly Energy
September 2012 Draft Strategic Plan for CREE Oslo Centre for Research on Environmentally friendly Energy This strategic plan is intended as a long-term management document for CREE. Below we describe the
More informationNational approach to artificial intelligence
National approach to artificial intelligence Illustrations: Itziar Castany Ramirez Production: Ministry of Enterprise and Innovation Article no: N2018.36 Contents National approach to artificial intelligence
More informationECA Statement on the 2010 World Programme of Population and Housing Censuses at the UN Statistical Commission
Statistical Commission Background document Thirty-seventh session Available in English only 7-10 March 2006 Item 4 (a) of the provisional agenda Item for information: Population and housing censuses ECA
More informationDraft global strategy on public health, innovation and intellectual property
IGWG: Outcome document at 14.00 hours, Saturday 3 May 2008 Draft global strategy on public health, innovation and intellectual property The context 1. In resolution WHA59.24 the Health Assembly recognized
More informationUpdate on Progress Implementing the LSIF Anti- Counterfeit Medicines Action Plan
2013/SOM1/LSIF/009 Agenda item: 17 Update on Progress Implementing the LSIF Anti- Counterfeit Medicines Action Plan Purpose: Information Submitted by: United States Life Sciences and Innovative Forum Planning
More informationHTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:
HTA Position Paper The Global Medical Technology Alliance (GMTA) represents medical technology associations whose members supply over 85 percent of the medical devices and diagnostics purchased annually
More information